Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR ...

–In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion–

Related Keywords

San Diego ,California ,United States ,Coherus Biosciences ,Narendiran Rajasekaran ,Theresa Lavallee ,Jodi Sievers ,Jami Taylor ,Abbvie Inc ,Exchange Commission On ,Nasdaq ,Exchange Commission ,Coherus Biosciences Inc ,Amgen Inc ,Corporate Communications ,Chief Development Officer ,Immune Checkpoints ,Inhibitory Molecules ,Fc Modified Igg ,Private Securities Litigation Reform Act ,Coheru Annual Report ,Contact Information ,